GRI Bio reported its full-year 2025 financial results, highlighting a strengthened balance sheet with sufficient cash to fund operations into Q1 2027, driven by recent capital raises. The company also presented positive Phase 2a clinical data for its lead IPF program, GRI-0621, reinforcing its therapeutic differentiation and advancing its pipeline.
Raised approximately $14.5 million in gross proceeds in December 2025 and January 2026.
positiveStrong cash position expected to fund planned operations into the first quarter of 2027.
positiveAnnounced positive Phase 2a topline data from the completed Phase 2a clinical study of GRI-0621 in idiopathic pulmonary fibrosis.
positiveReported additional data demonstrating suppression of pro-fibrotic immune phenotypes, reinforcing topline data and clinical proof-of-concept.
positiveNet loss of $12 million for the year ended December 31, 2025.
negativeResearch and development expenses increased by $3.0 million to $6.8 million for the year ended December 31, 2025, primarily due to expenses related to the registration development program of GRI-0621.
attentionGeneral and administrative expenses increased by $0.7 million to $5.2 million for the year ended December 31, 2025, primarily due to an increase in personnel costs.
attentionThe company's current cash position is assumed to fund only initial preparatory activities for GRI-0621, as substantial additional capital will be required to fund a Phase 2b clinical trial.
attentionMargin metrics will be available once backend extracts data from insights_json
In 2025, we prioritized disciplined clinical execution and balance sheet strength, delivering compelling clinical data from our lead IPF program which underscores the therapeutic differentiation of GRI‑0621.
Entering 2026 with a strong cash position, we are focused on advancing GRI-0621 in IPF, progressing GRI-0803 toward the clinic and executing our clinical strategy with capital discipline to drive long-term value creation.
The Company believes that its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.